-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec recently, Neurocrine Biosciences and Sosei Heptares announced a strategic cooperation and licensing agreement to jointly develop new selective muscarinic receptor agonists for the treatment of schizophrenia, dementia and Other neurological diseases
.
Muscarinic receptors are essential for brain function and have been verified as drug targets for psychosis and cognitive impairment
.
They belong to G protein coupled receptors (GPCR)
.
Approximately 34% of currently marketed drugs target GPCRs
.
However, since GPCRs are transmembrane proteins, it is often difficult to analyze their structures
.
Sosei Heptares' unique technology platform can maintain the integrity of the three-dimensional structure of GPCRs that have been stripped from the cell membrane, and can determine their structure combined with a variety of small molecule compounds
.
Based on this platform, the company has discovered a variety of selective muscarinic M4, M1 and M1/M4 dual agonists, which have potential therapeutic effects while avoiding the harmful side effects caused by non-selective agonists
.
Image source: 123RF According to the agreement, Neurocrine Biosciences will obtain the right to develop and commercialize the new selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei Heptares
.
The pilot project HTL-0016878 is a selective M4 agonist.
Neurocrine Biosciences plans to submit an IND application to the FDA in 2022 and initiate a phase 2 clinical trial evaluating it as a potential treatment for schizophrenia
.
HTL-0016878 has completed a number of phase 1 trials, showing good tolerability and safety
.
In addition to the M1 agonist being developed in Japan, Neurocrine Biosciences will be responsible for development costs related to global R&D projects
.
Sosei Heptares will receive a total of US$100 million in upfront payments and will be eligible for up to approximately US$2.
6 billion in R&D, regulatory and commercialization milestone payments, as well as tiered sales royalties
.
Dr.
Kevin Gorman, CEO of Neurocrine Biosciences, said: "Our collaboration with Sosei Heptares will leverage the strengths of our two organizations to work towards one goal at the same time
.
To bring important drugs to patients who need better treatment options
.
"Reference: [1] Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders.
Retrieved November 22, 2021, from https://neurocrine.
gcs-web.
com/news-releases/ news-release-details/neurocrine-biosciences-and-sosei-heptares-announce-collaboration Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for information exchange only.
The opinions in the article do not represent WuXi Kant's position does not mean that WuXi AppTec supports or opposes the views
in the
article .
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital
.
.
Muscarinic receptors are essential for brain function and have been verified as drug targets for psychosis and cognitive impairment
.
They belong to G protein coupled receptors (GPCR)
.
Approximately 34% of currently marketed drugs target GPCRs
.
However, since GPCRs are transmembrane proteins, it is often difficult to analyze their structures
.
Sosei Heptares' unique technology platform can maintain the integrity of the three-dimensional structure of GPCRs that have been stripped from the cell membrane, and can determine their structure combined with a variety of small molecule compounds
.
Based on this platform, the company has discovered a variety of selective muscarinic M4, M1 and M1/M4 dual agonists, which have potential therapeutic effects while avoiding the harmful side effects caused by non-selective agonists
.
Image source: 123RF According to the agreement, Neurocrine Biosciences will obtain the right to develop and commercialize the new selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei Heptares
.
The pilot project HTL-0016878 is a selective M4 agonist.
Neurocrine Biosciences plans to submit an IND application to the FDA in 2022 and initiate a phase 2 clinical trial evaluating it as a potential treatment for schizophrenia
.
HTL-0016878 has completed a number of phase 1 trials, showing good tolerability and safety
.
In addition to the M1 agonist being developed in Japan, Neurocrine Biosciences will be responsible for development costs related to global R&D projects
.
Sosei Heptares will receive a total of US$100 million in upfront payments and will be eligible for up to approximately US$2.
6 billion in R&D, regulatory and commercialization milestone payments, as well as tiered sales royalties
.
Dr.
Kevin Gorman, CEO of Neurocrine Biosciences, said: "Our collaboration with Sosei Heptares will leverage the strengths of our two organizations to work towards one goal at the same time
.
To bring important drugs to patients who need better treatment options
.
"Reference: [1] Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders.
Retrieved November 22, 2021, from https://neurocrine.
gcs-web.
com/news-releases/ news-release-details/neurocrine-biosciences-and-sosei-heptares-announce-collaboration Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for information exchange only.
The opinions in the article do not represent WuXi Kant's position does not mean that WuXi AppTec supports or opposes the views
in the
article .
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital
.
